Oxaliplatin Teva (Oxaliplatin)

Oxaliplatin Teva is a platinum‑based chemotherapeutic that acts on rapidly dividing cancer cells, particularly within the colorectal cancer pathway.

• Colorectal cancer: improves progression‑free survival when combined with fluorouracil and leucovorin.
• Gastric cancer: used in combination regimens for advanced disease.
• Pancreatic cancer: contributes to tumour response as part of multi‑drug protocols.

• Oxaliplatin forms reactive platinum complexes that covalently bind to DNA, creating intra‑ and interstrand cross‑links that inhibit DNA replication and transcription. This DNA damage triggers cell‑cycle arrest and apoptosis, preferentially affecting rapidly proliferating tumor cells while sparing most normal tissues.

Oxaliplatin Teva may cause a range of adverse reactions, most of which are dose‑dependent and reversible.

Common Side Effects

• Nausea and vomiting: mild to moderate gastrointestinal upset.
• Peripheral neuropathy: tingling or numbness, often transient.
• Fatigue: generalized tiredness during treatment cycles.
• Diarrhoea: loose stools that may require supportive care.
• Thrombocytopenia: reduced platelet count, increasing bleeding risk.
• Elevated liver enzymes: mild, transient rise in hepatic transaminases.

Serious or Rare Side Effects

• Severe neuropathy: persistent sensory loss that may be irreversible.
• Anaphylactic reactions: acute hypersensitivity requiring emergency intervention.
• Severe neutropenia: markedly low neutrophil count, raising infection risk.
• Cardiac arrhythmias: irregular heart rhythms observed in rare cases.
• Acute pulmonary toxicity: inflammation of lung tissue requiring prompt treatment.
• Hemolytic‑type transfusion reactions: rare immune‑mediated haemolysis.

Oxaliplatin Teva should be administered under the supervision of qualified oncology professionals, with appropriate monitoring and supportive care.

• Renal function assessment: evaluate creatinine clearance before each infusion.
• Hepatic function monitoring: check liver enzymes and bilirubin regularly.
• Neuropathy surveillance: assess sensory changes at each visit.
• Hematologic monitoring: complete blood count performed before each cycle.
• Premedication: consider anti‑emetic prophylaxis to reduce nausea.
• Store at ambient temperature: keep in original container, protect from light and moisture.

Oxaliplatin Teva may interact with several concomitant medications, influencing efficacy or toxicity.

Major Interactions (Avoid)

• Aminoglycoside antibiotics: increase risk of nephrotoxicity.
• High‑dose vitamin C: may reduce platinum‑drug activity.

Moderate Interactions (Monitor Closely)

• Anticoagulants anticoants: may enhance bleeding risk.
• Loop diuretics: potentiate electrolyte disturbances.
• NSAIDs: increase risk of renal impairment.
• CYP C‑